Skip to main
  1. Stocks
  2. Biogen
  3. Forecast
BIIB

Biogen (BIIB) Stock Forecast & Price Target

Biogen (BIIB) Analyst Ratings

Based on 24 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 29%
Sell 4%
Strong Sell 0%

Bulls say

Biogen is viewed positively because its legacy multiple sclerosis franchise remains a durable cash engine, while a diversified growth portfolio is increasingly offsetting decline and reducing loss-of-exclusivity risk. In 3Q26, revenues were about $2.8B, up 10.6% year over year, with non-GAAP EPS of $2.62 beating estimates and the growth portfolio contributing 63% of core pharmaceutical revenue, underscoring improving mix and operating resilience. The outlook is further supported by meaningful near-term catalysts across immunology and rare disease, including late-stage litifilimab, felzartamab, and zorevunersen readouts, plus strong momentum from Spinraza, Skyclarys, Leqembi, Syfovre, and Empaveli.

Bears say

Biogen is facing a structurally weakening core business, as its multiple sclerosis franchise remains the largest revenue generator yet is in decline and still accounted for 40% of total revenue in 2025. Its next-wave growth assets have yet to offset that pressure, with Leqembi, Skyclarys, and Zurzuvae all vulnerable to slower-than-expected sales ramps, while the CD20 collaboration with Roche, which contributed 19% of total revenue in 2025, also exposes the company to partner-driven and competitive dynamics. The bearish view is reinforced by the risk of ongoing clinical setbacks across programs such as SLE, CLE, AMR, and DS, alongside competitive pressure from LLY’s donanemab.

Biogen (BIIB) has been analyzed by 24 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 29% suggest Holding, 4% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Biogen and is not a guaranteed prediction by Public.com or investment advice.

Biogen (BIIB) Analyst Forecast & Price Prediction

Get the latest Biogen (BIIB) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Biogen (BIIB)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Biogen (BIIB) Forecast

Analysts have given Biogen (BIIB) a Buy based on their latest research and market trends.

According to 24 analysts, Biogen (BIIB) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $259.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $259.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Biogen (BIIB)


Biogen (BIIB) Analyst Forecast & Price Prediction

Get the latest Biogen (BIIB) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Biogen (BIIB)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover BIIB stock data and trends